Ignite Creation Date:
2025-12-24 @ 5:48 PM
Ignite Modification Date:
2026-01-27 @ 3:28 AM
Study NCT ID:
NCT01829568
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-27
First Post:
2013-04-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage III Grade 1 Follicular Lymphoma | View |
| None | Ann Arbor Stage III Grade 2 Follicular Lymphoma | View |
| None | Ann Arbor Stage III Grade 3 Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Grade 3 Follicular Lymphoma | View |
Keywords: